TITLE

GPC BIOTECH GETS GERMANY PERMITS FOR MONOCLONAL ANTIBODY

PUB. DATE
October 2003
SOURCE
Worldwide Biotech;Oct2003, Vol. 15 Issue 10, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that GPC Biotech AG has received three permits from the responsible German regulatory agency for the company's fully human oncology monoclonal antibody, 1D09C3, as of October 2003.
ACCESSION #
10935564

 

Related Articles

  • GPC Biotech cuts 15% of staff.  // PharmaWatch: Biotechnology;Oct2007, Vol. 6 Issue 10, p20 

    The article reports on the restructuring plan of GPC Biotech AG that involves the reduction of about 15 percent of its total workforce in the U.S. Bernd Seizinger, chief executive officer (CEO), extends his sincere appreciation to the affected employees for their services. The company also plans...

  • GPC Biotech presents new data supporting efficacy of anticancer monoclonal antibody.  // PharmaWatch: Biotechnology;October 2003, Vol. 2 Issue 10, p8 

    Reports on data presented by GPC Biotech AG on its anticancer monoclonal antibody, 1D09C3. Evaluation of the antibody in combination with Rituxan in an in vivo non-Hodgkin's lymphoma model; Synergistic effect of the two antibodies; Comparison of the cure rate of the combination therapy with...

  • GPC Biotech: satraplatin approval delay could prove costly.  // PharmaWatch: Monthly Review;Sep2007, Vol. 6 Issue 9, p7 

    The article reports that the New Drug Application for prostate cancer drug satraplatin was withdrawn by the GPC Biotech after an advisory panel's recommendation to wait for overall survival data before it can be approved. The GPC Biotech is making an effort to obtain the data quickly because it...

  • Satraplatin Reverberations: GPC Cutting 63 Positions. Sheridan, Cormac // BioWorld International;2/27/2008, Vol. 13 Issue 9, p1 

    The article reports on several rounds of job cuts initiated by GPC Biotech AG following the failure of its prostate cancer drug satraplatin. The latest round of job cuts will trim the company back to just 63 employees, which will primarily affect the company's early stage research activities in...

  • GPC BIOTECH MARKETING AUTHORIZATION APPLICATION WITHDRAWN.  // Worldwide Biotech;Sep2008, Vol. 20 Issue 9, p5 

    The article reports on the plan of GPC Biotech's partner for satraplatin in Europe to withdraw the Marketing Authorization Application (MAA) for the drug plus prednisone for the treatment of hormone-refractory prostate cancer patients. Such decision was based on a list of outstanding issues...

  • GPC Cuts Staff 44 Percent To Conserve Operating Cash. Osborne, Randall // BioWorld Today;11/16/2007, Vol. 18 Issue 224, p1 

    The article reports on the move by Martinsried, Germany-based GPC Biotech AG to reduce its staff. The company reduced its workforce by 44% as it deals with satraplatin setbacks and as it looks for new source of operating cash. The move is also part of the company's strategic plan that includes...

  • German Industry Beefs Up. Gopal, Kevin // Pharmaceutical Executive;Jun2001, Vol. 21 Issue 6, p32 

    Focuses on the growth of the biotechnology industry in Germany. Factors contributing to the industry's progress; Information on MediGene and GPC Biotech, beneficiaries of equity funding in the country; Overview of MediGene's products in development. INSET: Helping Hands.

  • GPC wins right to fight for pay.  // Pulse;5/3/2007, Vol. 67 Issue 17, p3 

    The article announces that GPC AG won its right to separate pay talks from general practice (GP) contract negotiations in Great Britain. It has been confirmed by the NHS Employers that negotiators could approach the pay review body rather than thrashing out an agreement. Linking inflationary pay...

  • GPC Biotech Enters Into Worldwide Drug Commercialization Agreement.  // Drug Discovery & Development;Oct2002, Vol. 5 Issue 9, p17 

    Reports that Munich, Germany-based company GPC Biotech AG has been granted an exclusive worldwide license to an orally-administered anticancer agent Satraplatin, according to an agreement with Irvine, California-based company NeoTherapeutics Inc. Terms of the agreement; Completion of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics